Shares of Kenvue Inc. retreated in late trading Thursday, pressured by a decline in the stock of suitor Kimberly-Clark Corp., which eroded the real-time value of the pending acquisition offer for the Tylenol maker. Kenvue stock closed down 1.6% at $17.39, while Kimberly-Clark shares fell 2.2% on the session.
Merger Math in Focus
The movement placed Kenvue's share price just below the calculated value of Kimberly-Clark's mixed cash-and-stock bid, which stood at approximately $17.81 per Kenvue share based on Thursday's closing prices. This created a narrow gap of about 42 cents—known on Wall Street as the merger arbitrage spread—between the current trading price and the offer's value.
This spread signals that investors continue to price in residual risks to the deal's completion, even after shareholders of both companies voted to approve the transaction in January. Primary concerns include the timing of regulatory approvals, potential regulatory hurdles, and ongoing litigation facing Kenvue.
Deal Structure and Market Pressure
As detailed in regulatory filings, the agreement entitles each Kenvue shareholder to receive $3.50 in cash plus 0.14625 of a Kimberly-Clark share for every Kenvue share they own. The 2.2% drop in Kimberly-Clark's stock on Thursday directly reduced the value of the stock component of the bid by roughly 33 cents.
The declines occurred against a backdrop of a broad market selloff. Major indices fell sharply, with the S&P 500 losing 1.52% and the Dow Jones Industrial Average dropping 1.56%. The selloff was fueled by rising oil prices approaching $100 per barrel amid geopolitical tensions. Other consumer staples giants like Procter & Gamble and Colgate-Palmolive each shed about 1.8%.
Operational Performance and Pending Challenges
Kenvue entered the trading day with some positive operational momentum. On February 17, the company reported fourth-quarter results that exceeded analyst forecasts, citing robust demand in its self-care and essential health segments. Concurrently, Kenvue announced plans to reduce its global workforce by approximately 3.5% ahead of the anticipated merger with Kimberly-Clark.
Chief Executive Kirk Perry noted that Kenvue concluded 2025 with "stronger top- and bottom-line performance" and emphasized the company's focus on finalizing the combination. Kenvue has stated it will not provide forward financial guidance while the deal remains pending.
Litigation Overhang Persists
Significant legal challenges remain a cloud over the proceedings. On February 26, a Texas judge denied Kenvue's motion to dismiss a lawsuit filed by Texas Attorney General Ken Paxton concerning Tylenol warning labels. Furthermore, Kenvue awaits an appeals court decision in more than 500 private lawsuits alleging a link between Tylenol use during pregnancy and autism.
When the deal was initially announced, analyst Robert Moskow of TD Cowen highlighted that Kimberly-Clark would be inheriting litigation risks that are difficult to quantify, a point that continues to resonate with investors.
Analyst Sentiment and Deal Timeline
According to market data, Kenvue currently holds a consensus analyst rating of "Hold" from 15 analysts, as of February 26. The fact that the stock is trading slightly below the offer value suggests the market still expects the acquisition to close, likely in the second half of 2026. However, the persistent discount indicates palpable hesitation regarding the final obstacles that must be cleared.
The transaction's fate now hinges on navigating the remaining regulatory landscape and legal uncertainties, with market participants closely watching the merger spread for clues about shifting confidence in a successful conclusion.
